Biopharma
Digital Health Strategy & Intelligence for Biopharma
Connect portfolio priorities, clinical evidence, external innovation, and market signals to make more defensible digital health decisions across the asset lifecycle.
Identify where digital capabilities can strengthen development, evidence generation, launch, patient support, or lifecycle value.
Evaluate venture maturity, strategic fit, evidence, partnerships, and execution risk before deeper engagement.
Track competitor partnerships, investments, trials, launches, and therapeutic-area priorities over time.
The decision context
Digital health creates value when it is tied to a pharmaceutical decision
Biopharma teams face an expanding field of digital biomarkers, decentralised trial tools, patient-support platforms, real-world evidence capabilities, and software-enabled therapeutics. The difficult part is not finding activity. It is deciding which capabilities are relevant to an asset or franchise, which partners can execute, and where the evidence supports commitment.
Galen Growth combines digital health advisory for biopharma with structured market intelligence. We connect portfolio strategy, digital due diligence and assessment (DDA), competitive movement, clinical evidence, startup and partner identification, and geographic market intelligence into one decision context.
What Galen Growth evaluates
Decision support across the biopharma lifecycle
Each engagement starts with the decision, then brings together the market, company, clinical, partnership, and execution evidence required to answer it.
Portfolio strategy
Map digital opportunities to therapeutic assets, franchises, and patient journeys, then prioritise where intervention can create measurable value.
Explore capability →02Digital due diligence and assessment
Pressure-test market claims, clinical evidence, partnership quality, organisational maturity, and strategic fit.
Explore capability →03Competitive intelligence
Monitor how peers deploy capital, form partnerships, build evidence, and position digital capabilities around priority assets.
Explore capability →04Startup and partner identification
Find ventures with the precise clinical, technical, geographic, and maturity profile required by the programme.
Explore capability →05Clinical evidence intelligence
Compare the relevance and strength of clinical, regulatory, and real-world evidence across candidate solutions.
Explore capability →06Geographic market intelligence
Understand ecosystem readiness, clinical-trial capability, local partnerships, and access conditions in priority markets.
Explore capability →Powered by HealthTech Alpha
A traceable view of ventures, evidence, and partnership activity
HealthTech Alpha links company profiles with funding, partnerships, products, clinical evidence, regulation, team, and market activity. Galen Growth analysts use that longitudinal record to distinguish a current capability from an old announcement and compare candidates against a relevant peer set.
Explore HealthTech Alpha- Therapeutic-area and technology mapping
- Clinical and regulatory evidence
- Partnership and competitor tracking
- Point-in-time venture maturity
Methodology
From strategic question to accountable action
- Frame the pharmaceutical decision
Define the asset, franchise, patient, evidence, market, and stakeholder requirements.
- Build the relevant universe
Map technologies, ventures, competitors, partnerships, and market signals against a governed taxonomy.
- Evaluate fit and evidence
Compare strategic relevance, maturity, clinical proof, partnership quality, and implementation constraints.
- Prioritise action
Deliver a defensible shortlist, portfolio recommendation, market roadmap, or monitoring programme.
Relevant work
How Galen Growth has supported related decisions
Tracking Competitor Moves to Support Global Franchise Strategy
Enabled leadership to make faster, more defensible portfolio and competitive-response decisions across core franchise areas.
Read case study →Case studyPrioritising Markets and Partners to Accelerate a Women’s Health Roadmap
Enabled the franchise to sequence market entry and focus partnership investment on a prioritised shortlist of ventures.
Read case study →Case studyPinpointing Oncology Ventures with Clinical Trial Capability in Emerging Markets
Enabled the clinical and BD teams to engage a short, highly qualified list of oncology ventures for further evaluation.
Read case study →Case studyPressure-Testing an Existing Digital Health Portfolio for Fitness to Scale
Enabled franchise leadership to re-prioritise, retire or deepen existing partnerships with confidence.
Read case study →Related intelligence
Research for this decision context
Explore Galen Growth analysis and reports built from the same digital health evidence base.
FAQ
Common questions
What does digital health strategy for pharma include?
It connects digital capabilities to pharmaceutical portfolio, asset, clinical-development, evidence, launch, patient-support, and lifecycle decisions rather than treating innovation as a separate activity.
How does Galen Growth identify digital health partners for biopharma?
We define the clinical, technical, geographic, evidence, and maturity requirements, map the relevant venture universe, and evaluate each candidate against consistent selection criteria.
Can the work support a single therapeutic area?
Yes. Engagements can focus on one asset or therapeutic area, a regional portfolio, or an enterprise-wide digital health strategy.
Who we help